@ARTICLE{
author={Petzer Andreas L,Wolf Dominik,Fong Dominic,Lion Thomas,Dyagil Irina,Masliak Zvenyslava,Boskovic Darinka V,Griskevicius Laimonas,Lejniece Sandra,Spasov Emil,Gercheva Liana,Stojanovic Aleksandar,Peytchev Dontcho,Tzvetkov Nikolay,Griniute Rasa,Stanchev Atanas,Kwakkelstein Martin,Ulmer Hanno,Gastl Guenther A},
year={2007},
title={Multicenter, randomized, phase III study comparing imatinib (Glivec) standard dose (400 mg/d) with imatinib high dose induction (800 mg/d) followed by imatinib maintenance (400 mg/d) in patients with pretreated Ph+/BCR-ABL(+) CML in chronic phase - Results from the first planned interim analysis (CELSG-CML 11 ISTAHIT study)},
journal={BLOOD},
volume={110},
number={11},
pages={317A-317A},
document_type={Meeting Abstract},
}